Publication Name	World Journal of Clinical Oncology
Manuscript ID	33609
Country	United States

Received	2017-02-20 09:46
Peer-Review Started	2017-02-23 08:18
To Make the First Decision	2017-06-14 01:08
Return for Revision	2017-06-28 14:54
Revised	2017-07-12 21:01
Second Decision	2017-08-11 07:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-08-16 18:42
Articles in Press	2017-08-16 18:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-13 06:40
Publish the Manuscript Online	2017-09-25 04:24

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Stereotactic radiotherapy for prostate cancer: A review and future directions
Manuscript Source	Invited Manuscript
All Author List	Yusef A Syed, Ami K Patel-Yadav, Charlotte Rivers and Anurag K Singh
Funding Agency and Grant Number
Corresponding Author	Anurag K Singh, Professor, Department of Radiation Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. anurag.singh@roswellpark.org
Key Words	Stereotactic body radiotherapy; Prostate cancer; Radiation therapy; Hypofractionation; Toxicity; Stereotactic ablative radiotherapy
Core Tip	Initial studies examining the use of stereotactic body radiotherapy (SBRT) in the treatment of prostate cancer have demonstrated impressive rates of biochemical recurrence-free survival and prostate specific antigen response, while maintaining a relatively favorable acute toxicity profile. Here we review a number of recent prospective and retrospective studies to evaluate the efficacy and toxicity of SBRT in the treatment of low, intermediate, and high-grade prostate cancer.
Publish Date	2017-09-25 04:24
Citation	Syed YA, Patel-Yadav AK, Rivers C, Singh AK. Stereotactic radiotherapy for prostate cancer: A review and future directions. World J Clin Oncol 2017; 8(5): 389-397
URL	http://www.wjgnet.com/2218-4333/full/v8/i5/389.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i5.389

Full Article (PDF)	WJCO-8-389.pdf
Full Article (Word)	WJCO-8-389.doc
Manuscript File	33609-Review.docx
Answering Reviewers	33609-Answering reviewers.pdf
Audio Core Tip	33609-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33609-Conflict-of-interest statement.pdf
Copyright License Agreement	33609-Copyright assignment.pdf
Peer-review Report	33609-Peer-review(s).pdf
Scientific Misconduct Check	33609-Scientific misconduct check.pdf
Scientific Editor Work List	33609-Scientific editor work list.pdf